Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media

Clicks: 1
ID: 319211
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #136 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: Acute generalized exanthematous pustulosis (AGEP) is a rare but severe skin eruption rarely induced by iodinated contrast media (ICMs). We report a clinical observation of AGEP induced by iodixanol with cross-reactivity with other ICMs, confirmed by positive intradermal tests (IDTs). SUMMARY: A 72-year-old female patient with no history of atopy, skin disease, or adverse drug reaction or allergy to iodine was diagnosed with acute coronary syndrome and underwent a rescue angioplasty using iodixanol as ICM. Four days later, the patient developed a morbilliform maculopapular rash with small nonfollicular pustules overspreading the entire body, accompanied by fever of 39.5 °C and vomiting. Laboratory investigations showed marked leukocytosis with neutrophilia and eosinophilia, and a high creatinine level. Clopidogrel was initially considered as the causative drug, and the patient was switched to ticagrelor, with a partial regression of the skin manifestations. However, 11 days after the angiography, the patient underwent a computed tomography scan using iodixanol, leading to a reactivation of the exanthema, accentuation of pustules, a high body temperature of 38.5 °C, and the reappearance of leukocytosis, neutrophilia, and eosinophilia. The diagnosis of AGEP was confirmed by a EuroSCAR score of 9, and iodixanol was highly suspected to be the culprit agent. Six weeks after the patient's complete recovery, an intradermal test with iodixanol was conducted according to the European Network of Drug Allergy (ENDA) recommendations, with the patient's informed consent, yielding a positive result at the 48-hour reading. To assess for cross-reactivity with other ICMs, IDTs with iopromide, iohexol, and iopamidol, were performed. All IDTs were positive at the 48-hour reading. CONCLUSION: We report a rare case of AGEP induced by iodixanol and point out the potential cross-reactivity between iodixanol, iopamidol, iopromide, and iohexol. IDTs for a wide range of ICMs should be conducted to identify safe alternatives for patients.
Reference Key
openalex_W7166816679 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hela Trimech, Haifa Ben Romdhane, M. Mahjoub, Zohra Chadli, Nadia Ben Fredj, Karim Aouam
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag196
URL
https://doi.org/10.1093/ajhp/zxag196
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.